Influence of BCR-ABL fusion proteins on the course of Ph leukemias

• Autorzy: Telegeev G. D. , Dubrovska A.N. , Dybkov M.V. , Maliuta S.S.
• Języki publikacji: EN

Abstrakty

EN

The hallmark of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) is the presence of the Philadelphia chromosome as a result of the t(9;22) translocation. This gene rearrangement results in the production of a novel oncoprotein, BCR/ABL, a constitutively active tyrosine kinase. There is compelling evidence that the malignant transformation by BCR/ABL is critically de­pendent on its Abl tyrosine kinase activity. Also the bcr part of the hybrid gene takes part in realization of the malignant phenotype. We supposed that additional muta­tions accumulate in this region of the BCR/ABL oncogene during the development of the malignant blast crisis in CML patients. In ALL patients having p210 fusion pro­tein the mutations were supposed to be preexisting. Sequencing of PCR product of the BCR/ABL gene (Dbl, PH region) showed that along with single-nucleotide substitutions other mutations, mostly deletions, had oc­curred. In an ALL patient a deletion of the 5th exon was detected. The size of the de­letions varied from 36 to 220 amino acids. For one case of blast crisis of CML changes in the character of actin organization were observed. Taking into account the functional role of these domains in the cell an etiological role of such mutations on the disease phenotype and leukemia progression is plausible.

Słowa kluczowe

EN

BCR-ABL gene; leukemia; chronic myeloid leukemia; tyrosine kinase; actin cytoskeleton; chronic neutrophilic leukemia; Philadelphia chromosome; hallmark; acute lymphoblastic leukemia

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2004
• Tom: 51
• Numer: 3
• Opis fizyczny: p.845-849,fig.,ref.

Twórcy

autor

Telegeev G. D.

• National Academy of Sciences of Ukraine, 150 Zabolotnogo str., Kyiv, Ukraine, 03143

autor

Dubrovska A.N.

autor

Dybkov M.V.

autor

Maliuta S.S.

Bibliografia

• Butturini A, Arlinghaus RB, Gale RP. (1996) Leuk Res.; 20: 523-9. Chomczynski P, Sacchi N. (1987) Anal Biochem.; 162: 156-9.
• Chuang TH, XuX, Kaartinen V, Heisterkamp N. (1995) Proc Natl Acad Sci USA.; 92: 10282-6.
• Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON. (1988) Science.; 239: 775-7.
• Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. (1995) Cancer.; 75: 464-70. Gishizky ML. (1996) Cytokines Mol Ther.; 2: 251-61.
• Gribble SM, Sinclair PB, Grace C, Green AR, Nacheva EP. (1999) Cancer Genet Cytogenet.; 111: 7-17. Kawasaki SS, Coyone MY. (1988) Proc Natl Acad Sci USA.; 85: 5698-2. Konopka JB, Watanabe SM, Witte ON. (1984) Cell.; 37: 1035-2. Laneuville P. (1995) Abl tyrosine protein kinase. Semin Immunol.; 7: 255-66.
• Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S. (1998) Br J Haematol.; 103: 711-5.
• Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Anderson BS, Arlinghaus RB. (1993) Oncogene.; 8: 101-9.
• Martinelli G, Amabile M, Giannini B, Terragna C, Ottaviani E, Soverini S, Saglio G, Rosti G, Baccarani M. (2002) Haematologica.; 87: 688-4.
• Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimono R. (1995) Blood.; 88: 2410-4. Quackenbush RC, Reuther GW, Pendergast AM. (1997) Blood.; 90: 247a.
• Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, de Micheli D, Parziale A, Fornaci MN, Martinelli G, SalvatoreF. (1996) Blood.; 87: 1075-80.
• Wulf E, DebobenA, BautzA, FaulstichH, Wieland Th. (1979) Proc Natl Acad Sci USA.; 76: 4498-2.